Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.

FC, Zhu; SY, Hu; Y, Hong; YM, Hu; X, Zhang; YJ, Zhang; QJ, Pan; WH, Zhang; FH, Zhao; CF, Zhang; X, Yang; JX, Yu; J, Zhu; Y, Zhu; F, Chen; Q, Zhang; H, Wang; C, Wang; J, Bi; S, Xue; L, Shen; YS, Zhang; Y, He; H, Tang; N, Karkada; P, Suryakiran; D, Bi; F, Struyf

doi:10.1002/cam4.2399

Public

Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.

Shared by NobleBlocks on Jul 15, 2019 • 12:00 AM UTC

Authors:

Zhu FC

Hu SY

Hong Y

Abstract

Background Cervical cancer is a major public health concern in China. We report the end-of-study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04-human papillomavirus (HPV)-16/18 vaccine in Chinese women aged 18-25 years followed for up to 72 months afte...

Subject

China

Safety

Immunogenicity

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!